Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 16 Sept 2005 |
| Orion Corporation applies for the listing of its stock options 2001C as of 3 October 2005 | 13 Sept 2005 |
| 5,500 Orion A-shares converted into B-shares | 24 Aug 2005 |
| Orion Group Interim Report 1-6/2005 | 9 Aug 2005 |
| Orion Diagnostica to transfer production from Oulunsalo to Turku | 15 Jun 2005 |